The Aspen timeline

Gross revenue R37,7 billion* 2016

Reached agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) to acquire the exclusive rights to commercialise AstraZeneca’s global anaesthetics portfolio in 100 countries worldwide, including China but excluding the USA. Anaesthetics have been identified as a key therapeutic category for the Group’s strategic development plans which will further strengthen Aspen’s presence in the hospital sector.

Gross revenue R33,5 billion 2015

The Group expanded its global presence into Ghana and New Zealand and increased the focus on its thrombosis portfolio across Europe and its infant nutritionals portfolio in Spanish Latin America and Asia Pacific in line with its previously defined strategy.

Gross revenue R31,4 billion 2014

Acquired an API business and a portfolio of branded FDF molecules from MSD as well as two branded injectable anticoagulants and a specialised sterile production site from GSK.

Aspen established a number of additional offices across Europe, the CIS and in Latin America, increasing coverage to more than 50 countries across the world.

Intellectual property rights in related infant nutritionals businesses in Latin America and South Africa were acquired from Nestlé.

Gross revenue R20,8 billion 2013

Acquired a portfolio of 25 established prescription-branded products from GSK (“classic brands”) with distribution rights in Australia effective in the 2013 financial year.

In May 2013 Aspen Australia commenced the distribution of the leading infant nutritional products in that country following the acquisition of the rights to certain intellectual property licences and the related business by the Group.

Gross revenue R16,4 billion 2012

Established its first subsidiary in South East Asia in the Philippines.

Aspen acquired a portfolio of established GSK over-the-counter (“OTC”) products in selected territories for R2,1 billion.

Gross revenue R13,2 billion 2011

Aspen acquired the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited, now Aspen Pharma (Pty) Limited, for R5,9 billion.

Gross revenue R10,1 billion 2010

Took full control of the Latin American businesses acquired in 2008.

Gross revenue R8,4 billion 2009

Concluded a series of strategic transactions with GSK worth R4,6 billion comprising the acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa, the formation of the GSK Aspen Healthcare for Africa Collaboration (“the SSA Collaboration”) to market and sell pharmaceuticals in SSA, the acquisition of eight specialist branded products for worldwide distribution and the acquisition of a manufacturing site in Bad Oldesloe, Germany.

Gross revenue R4,7 billion 2008

Entered the Latin American market through an investment with Strides in businesses established in Brazil, Mexico and Venezuela.

Acquired 60% of the share capital of Shelys with businesses in Kenya, Tanzania and Uganda.

AGI acquired the intellectual property rights to four GlaxoSmithKline Plc (“GSK”) branded products for R2,7 billion, enabling Aspen to distribute these global brands, namely Eltroxin, Imuran, Lanoxin and Zyloric, to more than 100 countries.

Gross revenue R4,0 billion 2007

Prestige Brands Incorporated entered into an agreement with Aspen for the supply of eye drops from Aspen’s Sterile facility in Port Elizabeth to the USA market.

Gross revenue R3,4 billion 2006

Secured distribution rights for a number of important ARVs from Merck Sharpe & Dohme (“MSD”), Bristol Myers Squibb, Roche and Tibotec as the Group extended its portfolio as the biggest supplier of anti-retrovirals (“ARVs”) in Africa.

Gross revenue R2,8 billion 2005

Extended its BBBEE ownership through the conclusion of an empowerment transaction with Imithi Investments (Pty) Limited.

Aspen’s Unit 1 facility in Port Elizabeth became the world’s first manufacturing site to receive tentative US FDA approval for the production of certain generic ARVs.

    2004

Aspen acquired FCC, the only South African manufacturer of APIs.

Aspen acquired Infacare, the infant nutritionals brand, from Dutch-based Royal Numico.

Aspen’s multi-million Rand Port Elizabeth-based Unit 1 facility became operational.

    2003

Entered into a fostering arrangement with GSK for the marketing and distribution of 40 branded products into the South African private sector.

Aspen Stavudine was launched – Africa’s first generic ARV.

    2002

Concluded a BBBEE deal with CEPPWAWU Investments (Pty) Limited, the investment arm of the trade union representing the majority of Aspen’s labour force in South Africa.

Aspen’s new corporate identity was launched symbolising energy, innovation and nurturing.

    2001

Aspen Australia commenced trade as a start-up operation.

Nelson Mandela officiated at the opening of a clinic constructed for the disadvantaged citizens of Engcobo, South Africa, the first of the community clinics established under Aspen’s SED programme.

    2000

Commenced construction of an oral contraceptive facility at its East London site.

    1999

Acquired the pharmaceutical business of South African Druggists for R2,4 billion in a hostile take-over.

    1998

Listed on the JSE through reverse listing into Medhold Limited.

    1997

Aspen Healthcare (Pty) Limited began trading with Stephen Saad and Gus Attridge as two of the four founding members.

    1850

The commencement of the business in Port Elizabeth, South Africa, which later became Lennon Limited, the originator company to the Group today.

* Comparable revenue excludes the contribution from divestments and includes the results of Aspen’s Venezuelan business translated at the DICOM (previously SIMADI) rate of VEF628,34 per USD for the prior reporting period.